INTRODUCTION
Lysophosphatidic acid (LPA) has attracted recent attention as a serum-derived regulator implicated in responses to vascular injury and inflammation, in neurite retraction and neuronal signalling, and in tumour invasiveness (reviewed in ref [1] ). Controversy concerning its mechanism may be due, in part, to species-specific and cell-specific differences, and to stimulation of several different intracellular signalling pathways. Mitogenic effects in fibroblasts require high (1-100 µM) LPA concentrations, are not affected by long-term treatment with phorbol esters, but are blocked with Pertussis toxin or suramin [2, 3] . In contrast, rapid increases in intracellular Ca# + require lower LPA concentrations [2, [4] [5] [6] [7] , are blocked by phorbol ester treatment [2, 4] and vary in their response to Pertussis toxin. More recently, tyrosine kinase cascades have also been implicated in the action of LPA. Activation of Ras, Raf and the mitogen-activated protein (MAP) kinase pathway have been demonstrated, as have activation of src and focal adhesion kinase (reviewed in ref. [1] ).
It has been suggested on the basis of the following arguments that the Ca# + and mitogenic effects of LPA are mediated by a Gprotein-coupled receptor : (a) the effects are dependent on GTP [2, 8] ; (b) the kinetics and shape of the LPA-induced response are similar to those of similarly acting hormones [4] ; (c) the LPA effect is subject to homologous desensitization [4, 8] ; (d) the LPAinduced phospholipid hydrolysis is cell-type specific, cells of haematopoietic origin failing to respond [4] ; (e) the effects are blocked by the addition of suramin (reported to be membraneimpermeant [9] ) outside the cells [3, 6] ; (f) the LPA effect on Abbreviations used : LPA, lysophosphatidic acid ; PKC, protein kinase C ; LPC, lysophosphatidylcholine ; PC, phosphatidylcholine ; PS, phosphatidylserine ; DAG, diacylglycerol ; DMPS, dimyristoyl-PS ; DMPC, dimyristoyl-PC ; DOPS, dioleoyl-PS ; DOPC, dioleoyl-PC ; DSC, differential scanning calorimetry ; SUV, small unilamellar vesicle ; MLV, multilamellar vesicle ; LUV, large unilamellar vesicle ; MAP kinase, mitogen-activated protein kinase.
* To whom correspondence should be addressed. In unsaturated PC\PS vesicles, very little to no effect of LPA was discernable. These results suggest that physiologically or pathologically relevant concentrations of LPA can contribute to PKC activation depending on the composition of the lipid membrane. We hypothesize that LPA may affect the formation of lipid domains that are recognized by the enzyme.
Xenopus oocytes is not mimicked by intracellular LPA injection [5, 6] . Although, to date, no success has been reported in cloning such a receptor, there is one report of a binding protein of 38-40 kDa identified by cross-linking with a [$#P]LPA analogue containing a photoactivatable acyl chain [10] . However, a similar LPA-binding protein was also observed in several haematopoietic cells [10] that failed to respond to LPA [4] . Problems with nonspecific binding of LPA and potential metabolism make this work difficult but also weaken some of the arguments for a specific receptor. Since LPA can lead to protein kinase C (PKC) activation in various cells [2] and phorbol ester activators of PKC can also stimulate tyrosine phosphorylation pathways [11] [12] [13] , modulate G-proteins [14] [15] [16] [17] and lead to mitogenic effects via activation of the MAP kinase pathway [18] , we considered that LPA might exert some of its effects through PKC without the need for an additional specific receptor protein. PKC can also be activated or inhibited by suramin, depending on the concentration [19, 20] , can down-regulate a number of membrane receptors (reviewed in ref. [21] ) and can stimulate or inhibit phospholipid hydrolysis in many cell types (reviewed in ref. [22] ). PKC is affected by numerous products of phospholipid metabolism (reviewed in ref. [22] ) and many other lipid-soluble molecules. Another phorbol-ester-binding protein, n-chimaerin, which has a p21 rac GTPase-activating protein domain in place of the kinase domain of PKC, was inhibited by LPA in a purified in itro system and this inhibition required the lipid cofactors and the cysteine-rich phorbol-esterbinding region of n-chimaerin that is shared with PKC [23] .
However, although low concentrations ( 20 µM) of lyso-phosphatidylcholines (LPC) have been shown to activate PKC in itro and higher concentrations to inhibit, very little effect of LPA was observed in those studies [24, 25] . Similarly, LPC was effective in stimulating PKC pathways in haematopoietic cells including lymphocytes [26] , HL60 cells [27] and mast cells [28] , as well as in endothelial cells [29] , all of which failed to respond to LPA ; but LPC was not effective in stimulating the cells that respond to LPA with mitogenesis or increased Ca# + [2] . Such cellular differences contribute to the argument for the presence of specific LPA or LPC receptors. However, Sasaki et al. [25] have reported differential responses of PKC isoenzymes to LPC, with PKC α, β, γ and δ being activated maximally at 4 µM LPC in the absence of Ca# + and PKC α, β and γ being maximally activated at 10-20 µM phosphatidylcholine (PC) in the presence of Ca# + followed by inhibition at higher concentrations, but inhibition only observed with PKC ε. Thus it is possible that expression of different PKC isoenzymes in different cells may account for the differential response to the different lysolipids. Another possibility is that the effect of the lysolipids varies as a function of the differing membrane lipid composition of different cell types. In addition to changes in concentrations of its cofactors phosphatidylserine (PS), diacylglycerol (DAG) and Ca# + , PKC is also sensitive to changes in physical properties of the membrane (reviewed in ref. [30] ). A dependence on phospholipid acyl chain unsaturation was observed but saturated PC\PS vesicles could be rendered effective at very high concentrations of DAG [31] . Analysis of this saturated lipid system with various DAG concentrations by differential scanning calorimetry (DSC) and Fourier-transformed IR spectrometry suggests that the formation of DAG\PS-rich domains is associated with PKC activation [32] . Using vesicle systems with these defined compositions, we have re-examined the possibility that LPA may affect PKC more directly.
EXPERIMENTAL Materials
Lysine-rich histone and bovine brain PS were from Sigma. LPA, LPC, dimyristoyl-PS (DMPS), dimyristoyl-PC (DMPC), dioleoyl-PC (DOPC), dioleoyl-PS (DOPS) and diacylglycerol (DAG) were from Avanti Polar Lipids. [$#P]ATP (7000 Ci\mmol) was obtained from ICN and adjusted to a specific radioactivity of 1.5-2.9 mCi\mmol for kinase assays. [$H]Phorbol 12,13-dibutyrate (18.6 Ci\mmol) was from Dupont-NEN. Fetal calf serum was from Gibco and yeastolate and lactalbumin were from Difco. A polyclonal anti-PKCα antibody directed against the catalytic domain was obtained from Santa Cruz Biotechnology.
Preparation of lipids
Small unilamellar vesicles (SUVs) were prepared from the lipids just before assay. Purity of lipid stocks was confirmed by TLC and concentrations were determined by phosphate assay [33] . Lysophospholipids, phospholipids and DAG stocks in chloroform were mixed together in various molar ratios as indicated in the Figures, dried under a stream of N # gas and then under vacuum overnight. The samples were rehydrated with 20 mM Mops buffer, pH 7.5, in the dark, and sonicated to make SUVs. Multilamellar vesicles (MLVs) were prepared from the same stocks by vortexing rather than sonicating the preparations. For some experiments, large unilamellar vesicles (LUVs) were prepared by extruding the MLVs through a 100 nm membrane 31 times in a hand-held extruder (Avestin). Characterization of the LUVs by light scattering revealed an average diameter of approx. 
Purification of PKC
PKCα was purified from Sf9 cells infected with PKCα-containing baculovirus generously provided by Dr. Peter Parker, Dr. Silvia Stabel and Dr. Doriano Fabbro. Enzyme was purified by sequential chromatography on Q-Sepharose and phenylSepharose as described [34] . Purity was verified by PAGE followed by silver staining and Western blotting with isoenzymespecific antibodies. Purified PKC was brought to 30 % (v\v) glycerol and stored at k70 mC. Enzyme concentration was determined by measuring binding of [$H]phorbol 12,13-dibutyrate as described previously [35] .
Assay of PKC activity
PKC activity was determined by its ability to transfer phosphate from [$#P]ATP to lysine-rich histone. The standard reaction mixture (75 µl total) contained 2-4 nM PKC, 0.2 mg\ml histone, 40 µM [$#P]ATP (2.5i10$-5i10$ c.p.m.\pmol), 5 mM magnesium acetate, 300 µM CaCl # , 20 mM Mops buffer, pH 7.5, and vesicles of various composition (67 µM-6 mM). Reactions were started by the addition of the substrates to tubes containing enzyme and lipid vesicles and terminated after 5 min at 30 mC by spotting 60 µl on to P-81 ion-exchange paper (Whatman). Papers were washed in 50 mM NaCl to remove unchanged ATP and dried. Bound radioactivity was determined by C B erenkov counting.
RESULTS
To test the hypothesis that LPA might affect PKC activation in a manner that was dependent on the lipid composition of the membrane vesicle, we examined the effect of [18 : 1]-LPA on baculovirus-expressed PKCα in the DMPC\DMPS lipid system, the physical properties and PKC-activating ability of which are strongly dependent on the mol % of DAG. At near maximal DAG concentrations (15 mol %), LPA activated PKC, but the concentration required for maximal activation was dependent on the total lipid concentration. Maximal stimulation occurred at 10 µM LPA in 50 µM lipid but at 100 µM LPA in 500 µM or 3 mM lipid. Higher LPA concentrations were inhibitory.
Since the stimulation with LPA was less at the higher lipid concentrations, we asked whether LPA was simply replacing total lipid in activating the enzyme. Figure 1 shows that the addition of 25 µM LPA provided an approx. 2-fold greater PKC activation than maximally effective concentrations of SUVs. The increase was maximal between 2 and 16 mol % LPA and the stimulation was greater at suboptimal concentrations of lipid. In the absence of phospholipid vesicles, LPA did not activate PKC at any concentration (results not shown).
The concentration-dependence of the LPA effect was examined at maximal PKC-activating concentrations (3.2 mM) of DMPC\ DMPS\DAG (60 : 25 : 15, molar ratio), and again, maximal activity occurred at 11-16 mol % LPA in both SUVs and MLVs (Figure 2) . To determine whether similar-sized vesicle structures were formed at all LPA concentrations, LUVs were prepared at each lipid concentration and examined by light scattering for uniformity of size distribution. All preparations exhibited the same uniform Gaussian distribution. Again, maximal activity occurred at 11-16 mol % LPA, although the LUVs often produced increased total activation (Figure 2 ).
To determine whether LPA was replacing the PKC requirement for PS, the assays were carried out with varying mol % PS and at several LPA concentrations. Figure 3(A) shows that addition of 100 µM (approx. 3 mol %) LPA provided greater activation than maximally effective concentrations of PS and that 200 µM LPA (approx. 6 mol %) provided a minimal additional increase in the maximal activity, but significantly decreased the concentrations of PS required for maximal ac- tivation. As shown in Figure 3 (B), LPA had no effect at all in the absence of PS.
Figures 4(A) and 4(B) show that LPA was similarly ineffective in the absence of DAG, nor did it significantly affect the concentration of DAG required. Figure 4 (C) reveals that LPA failed to affect PKC activation in the unsaturated lipid (DOPC\ DOPS) system. This system requires very little DAG for maximal PKC activity, but LPA did not affect this DAG requirement ( Figure 4D) . Similarly, LPA did not alter the Ca# + requirement for activation of PKCα (results not shown).
The specificity of the LPA activation of PKC was examined by comparing several LPA and LPC species varying in acyl chain. Figure 5 shows that oleoyl (18 : 1) LPA and LPC provided similar maximal PKC activation, with LPC causing stimulation and inhibition at lower concentrations. The long-chain saturated LPC and LPA were minimally effective but the shorter-chain saturated (14 : 0) LPA was moderately effective.
Since minimal LPA effects were observed in previous reports that showed substantial effects of LPC [24, 25] , we compared the two lysolipids in the mixed acyl chain bovine PS used in previous studies as well as in the saturated and unsaturated PC\PS systems. As shown in Figure 6 , both LPC and LPA caused a dramatic activation of PKC in the DMPC\DMPS system whereas neither was effective in the unsaturated lipid system. In bovine brain PS, LPC caused a 20 % increase in PKCα activity, as observed previously [25] , whereas the LPA effect was much less. As with LPA (Figure 2 ), LPC inhibited PKCα at high concentrations and was more potent than LPA in this inhibitory effect.
In order to investigate a possible LPA effect on the physical significantly affected the melting behaviour of these lipid mixtures by broadening the main gel\liquid crystalline phase transition.
DISCUSSION
Whereas previous studies have revealed significant effects of LPC on PKC activity in itro, very little PKC activation was observed with LPA [24, 25] . In contrast, we observed a significant ( 2-fold) increase in PKC activity with LPA (Figures 1 and 2 ). The explanation for the different effects is probably the acyl chain composition of the phospholipid system used to activate the enzyme. Only in saturated phospholipids was the effect dramatic. In fully unsaturated PC\PS systems, which produce maximal PKC activation with minimal DAG, LPA effects were minimal (Figures 4 and 6) . The previous studies used bovine brain PS, which contains a mixture of acyl chains, largely unsaturated, to activate PKC. Using this system, we also observed about a 20 % increase in maximal activity with LPC and a marginal effect of LPA.
As with the LPC activation of PKC characterized previously [24, 25] , we found that the LPA activation was dependent on the presence of DAG and did not change the concentrations of DAG required (Figure 4 ). The effect of LPA was also dependent on the presence of PS, although it could decrease significantly the concentration of PS required for maximal activity and, again, double the maximal activation at maximally effective concentrations of PS (Figure 3 ). This effect may be similar to that reported previously [36, 37] in which other acidic lipids could replace part, but not all, of the requirement for PS.
Since purified PKC and defined lipid systems were used in the present study, the LPA effects observed cannot be attributed to binding to a separate LPA receptor. It is also unlikely that the effects are mediated by direct binding to PKC. First, LPA was ineffective in the absence of phospholipid PKC activators. Secondly, the biphasic LPA effects (Figure 2 ) cannot be explained by interaction with a single site. Thirdly, the concentration of LPA required was dependent on total lipid (Figure 1 ) and on the mol % of PS ( Figure 3 ) and was not directly related to PKC concentration (results not shown). These results and the dependence on acyl-chain properties of both the phospholipid and the LPA (Figures 4-6 ) support the hypothesis that LPA affects PKC by altering the physical properties of the lipid. In support of this hypothesis, LPA was observed to broaden the main (gel\liquid crystalline) phase transition observed by DSC when incorporated into DMPC\DMPS\DAG MLVs (Figure 7 ). These data are consistent with the enhanced formation of distinct lipid domains exhibiting overlapping phase transitions.
The difference in the effects of LPA in saturated and unsaturated phospholipid systems suggests that one role of LPA may be to contribute unsaturation to the phospholipid system. As shown previously [31] , minimal DAG was required to activate the enzyme in unsaturated PC\PS vesicles, whereas activity could be achieved in saturated lipid systems only with large increases in the DAG content. Consistent with the importance of unsaturation is the observation that unsaturated LPA and LPC are most efficacious ( Figure 5 ). Partial activation was observed with [14 : 0]-LPA but longer-chain saturated lysolipids were ineffective. This result differs from those showing very good activation of PKC with [16 : 0]-LPC [24, 25] . Part of the explanation for this difference may be the different phospholipid systems and concentrations used obovine PS at 10 µg\ml [24] or 4 µM [25] compared with DMPC\DMPS at 100 µM (Figure 6 )q. Some of the LPC effect observed previously may have been due to the increase in total lipid concentration.
The effectiveness of saturated lysolipids and differences in effectiveness of LPC and LPA may also depend on the background phospholipid composition and physical properties. Examination of the DMPC\DMPS\DAG system via DSC and Fourier-transformed IR spectroscopy is consistent with the formation of distinct PS-and DAG-enriched lipid domains, in association with activation of PKC [32] . An association of PKC activity with PS-substrate domains has also been visualized recently in large PC\PS\DAG vesicles [38] . We hypothesize that LPA and other lysolipids may alter the formation of these domains, and that their ability to do so may depend, in part, on the acyl chains of both the lysolipid and the surrounding phospholipid, and also on the headgroup charge of both. Thus, in a system comprised of only the optimal acidic phospholipid, PS, addition of more acidic headgroup in the form of LPA may not help, whereas LPC may promote domain formation more effectively. The effectiveness of saturated compared with unsaturated lysolipids may depend on their acyl-chain mismatch with the surrounding lipid. The ability of LPA or LPC to affect PKC activity in a given cell may therefore depend on the phospholipid composition and physical properties of that cell's membrane in addition to variables such as PKC isoenzyme expression and the generation of other activators such as Ca# + and DAG.
The concentrations of LPA (1-3 mol %) that could activate PKC under some conditions in itro were well within the range expected in physiological (or pathological) settings. Even the maximal effects of 11-16 mol % (300-500 µM at 3.2 mM total lipid) may have physiological significance if it is remembered that these in itro lipid systems do not represent models of the whole cell membrane, but only of small subsets of lipid domains that may form within the whole membrane. We do not yet know the concentrations of LPA that may be found within specific lipid domains relevant to PKC activation in intact cells, but certainly these concentrations will be much higher than those relating LPA to total cellular phospholipids. Thus it is possible that direct activation of PKC may contribute to some cellular responses to LPA in the absence of a specific LPA receptor. The response observed in a given cell would depend on the PKC substrates (G-proteins, receptors, MAP kinase and other signalling pathway components) having access to the activated PKC isoenzymes in that cell.
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